Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy

Area of Science:

• Cardiovascular Biology
• Cell Signaling
• Molecular Medicine

Background:

• Angiopoietins were traditionally considered endothelial cell-specific, acting via the Tie2 receptor.
• Angiopoietin-1 (ang1) monomers interact with integrins on cardiac myocytes (CMs), promoting cell survival.
• The distinct functions of ang1 monomers and multimers in cardiac remodeling require further investigation.

Purpose of the Study:

• To investigate the in vivo function of ang1 monomers in cardiac remodeling.
• To examine ang1 monomer and multimer expression during physiological and pathological cardiac changes.
• To assess the therapeutic potential of overexpressing ang1 monomers in cardiac hypertrophy.

Main Methods:

• Analysis of ang1 mRNA and protein levels during cardiac development and hypertrophy.
• Western blotting to differentiate ang1 monomer and multimer expression.
• Overexpression of ang1 monomers (ang1-256) in mice subjected to phenylephrine-induced cardiac hypertrophy.
• Assessment of cardiac structure, gene expression, fibrosis, and signaling pathways (Tie2, integrin-linked kinase, Akt, MAPK, AMPK).

Main Results:

• Cardiac ang1 levels changed during remodeling, primarily involving monomers, with unchanged Tie2 phosphorylation.
• Overexpressed ang1 monomers reduced cardiac hypertrophy indicators (LV/tibia ratio, fetal gene expression, fibrosis).
• Ang1 monomers enhanced prosurvival signaling (Akt, MAPK, AMPK) and increased integrin-linked kinase activity in hypertrophied hearts.

Conclusions:

• Angiopoietin-1 monomers play a significant role in cardiac remodeling, distinct from Tie2 signaling.
• Ang1 monomers promote cardiac health and survival through integrin activation.
• Targeting ang1 monomers represents a potential therapeutic strategy for cardiac diseases.